Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections

Almirall

Status and phase

Completed

Phase 2

Conditions

Candidiasis

Treatments

Drug: LAS41003

Drug: LAS189961

Drug: LAS189962

Study type

Interventional

Funder types

Industry

Identifiers

NCT01102387

2009-016627-56 (EudraCT Number)

H 552 000 - 0920

Details and patient eligibility

About

The aim of this study is to determine the efficacy and safety of once daily topical application of the combinational cream LAS41003 compared to the corresponding mono-substances in the treatment of candida infections in intertriginous areas at the trunk.

Enrollment

137 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

presence of candida infections in one or more intertriginous areas (trunk), confirmed by positive mycological sample at baseline;
female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner;
written informed consent

Exclusion criteria

receiving systemic therapy with cytotoxic or immunosuppressive drugs either concurrently or within 12 weeks before the baseline visit;
patients who have been treated with oral anti-fungal agents within the 12 weeks prior to study entry or treated with topical anti-fungal agents on the intertrigines within the previous 2 weeks;
evidence of drug or alcohol abuse;
pregnancy or nursing;
symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study;
treatment with any other investigational drug in the four weeks preceding the study;
known allergic reactions to components of the study preparations, hypersensitivity against cetylstearyl alcohol;
treatment with systemic or locally acting medications which might counter or influence the study aim within two weeks before the beginning of the study (e.g. glucocorticosteroids);
in the opinion of the investigator or physician performing the initial examination the subject should not participate in the study, e.g. due to probable non-compliance or inability to